Cetero preps for new owner after filing for bankruptcy protection

Despite filing for Chapter 11 bankruptcy protection Monday, the Cary, NC-based CRO Cetero insists it has no plans to cease daily operations or ongoing research. And if all goes as planned, Cetero will find itself under new ownership within the next 120 days. "Throughout the reorganization process there will be no change to day‐to‐day operations at any of Cetero's facilities. Each and every one will continue to run and actively take on new studies," Cetero said in a statement to FierceCRO.  Report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.